PT  - JOURNAL ARTICLE
AU  - Khan, Yousef
AU  - Davis, Christal N.
AU  - Jinwala, Zeal
AU  - Feuer, Kyra L.
AU  - Toikumo, Sylvanus
AU  - Hartwell, Emily E.
AU  - Sanchez-Roige, Sandra
AU  - Peterson, Roseann E.
AU  - Hatoum, Alexander S.
AU  - Kranzler, Henry R.
AU  - Kember, Rachel L.
TI  - Combining Transdiagnostic and Disorder-Level GWAS Enhances Precision of Psychiatric Genetic Risk Profiles in a Multi-Ancestry Sample
AID  - 10.1101/2024.05.09.24307111
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.09.24307111
4099  - http://medrxiv.org/content/early/2024/05/10/2024.05.09.24307111.short
4100  - http://medrxiv.org/content/early/2024/05/10/2024.05.09.24307111.full
AB  - The etiology of substance use disorders (SUDs) and psychiatric disorders reflects a combination of both transdiagnostic (i.e., common) and disorder-level (i.e., independent) genetic risk factors. We applied genomic structural equation modeling to examine these genetic factors across SUDs, psychotic, mood, and anxiety disorders using genome-wide association studies (GWAS) of European-(EUR) and African-ancestry (AFR) individuals. In EUR individuals, transdiagnostic genetic factors represented SUDs (143 lead single nucleotide polymorphisms [SNPs]), psychotic (162 lead SNPs), and mood/anxiety disorders (112 lead SNPs). We identified two novel SNPs for mood/anxiety disorders that have probable regulatory roles on FOXP1, NECTIN3, and BTLA genes. In AFR individuals, genetic factors represented SUDs (1 lead SNP) and psychiatric disorders (no significant SNPs). The SUD factor lead SNP, although previously significant in EUR- and cross-ancestry GWAS, is a novel finding in AFR individuals. Shared genetic variance accounted for overlap between SUDs and their psychiatric comorbidities, with second-order GWAS identifying up to 12 SNPs not significantly associated with either first-order factor in EUR individuals. Finally, common and independent genetic effects showed different associations with psychiatric, sociodemographic, and medical phenotypes. For example, the independent components of schizophrenia and bipolar disorder had distinct associations with affective and risk-taking behaviors, and phenome-wide association studies identified medical conditions associated with tobacco use disorder independent of the broader SUDs factor. Thus, combining transdiagnostic and disorder-level genetic approaches can improve our understanding of co-occurring conditions and increase the specificity of genetic discovery, which is critical for psychiatric disorders that demonstrate considerable symptom and etiological overlap.Competing Interest StatementDr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics; and a holder of U.S. patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists,” issued 26 January 2021.Funding StatementThis study is supported by NIH grants K01AA028292 (R.L.K.), R01MH125938 (R.E.P.), P50AA022537 (R.E.P.), T32 HG009495 (K.L.F.), the Brain & Behavior Research Foundation NARSAD grant 28632 PS Fund (R.E.P.), the California Tobacco-Related Disease Research Program (TRDRP; T32IR5226) (S.S-R), the Department of VA Office of Research and Development grants IK2 CX002336 (E.E.H.), I01 BX003341 (H.R.K.) and the Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center. This publication does not represent the views of the Department of VA or the United States Government. We acknowledge the Penn Medicine BioBank (PMBB) for providing data and thank the patient-participants of Penn Medicine who consented to participate in this research program. We would also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is approved under IRB protocol #813913 and supported by the Perelman School of Medicine at the University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA award number UL1TR001878.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used publicly available GWAS summary statistics released by the authors of the studies in Table 1 and Supplementary Tables 1-4. The data sources (including links) are described in the data availability statement.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesGWAS Summary Statistics used for the present study can be accessed at the following locations: UK Biobank (http://www.nealelab.is/uk-biobank/), dbGaP accession phs001672 for Million Veteran Program (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001672), iPSYCH (https://ipsych.dk/en/research/downloads/), Psychiatric Genetics Consortium (https://pgc.unc.edu/for-researchers/download-results/), the Social Science Genetic Association Consortium (https://thessgac.com/), GWAS catalog (https://www.ebi.ac.uk/gwas/publications/28979981; https://www.ebi.ac.uk/gwas/publications/33532862), Gelernter Lab website (https://medicine.yale.edu/lab/gelernter/stats/), Global Biobank Meta-analysis Initiative (https://www.globalbiobankmeta.org/resources), and the Diabetes Genetics Replication and Meta-Analysis Consortium (https://diagram-consortium.org/downloads.html). Once accepted for publication, summary statistics for the first-order, second-order, and GWAS-by-subtraction analyses will be made publicly available.